What happened
Four Alzheimer's blood tests now have FDA clearance, including PrecivityAD2 and Roche's Elecsys pTau217. As Time reported, experts agree they belong in the workup of patients with cognitive symptoms, not in screening healthy people, because false positives rise in low-risk groups. Have a clear policy for when to order one and what to do if a patient brings you a result obtained outside that pathway. Time
Originally published in The Longevity Medicine Intelligence newsletter (#108).
WRITTEN BYlongevitydocs™ editorsCurated by the longevitydocs™ editorial team from the weekly newsletter
